Literature DB >> 30605659

The Structure of HPK1 Kinase Domain: To Boldly Go Where No Immuno-Oncology Drugs Have Gone Before.

Sansana Sawasdikosol1, Steven Burakoff2.   

Abstract

In this issue of Structure, Wu et al. (2018) report several apo and small-molecule inhibitor-bound structures of the kinase domain of hematopoietic progenitor kinase 1, a ser/thr kinase that functions as an inhibitor of T cell activation. The studies reveal that the HPK1 kinase domain exists as a domain-swapped dimer.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30605659     DOI： 10.1016/j.str.2018.12.009

Source DB:  PubMed          Journal:  Structure        ISSN： 0969-2126            Impact factor:   5.006


  3 in total

1.  Multiple conformational states of the HPK1 kinase domain in complex with sunitinib reveal the structural changes accompanying HPK1 trans-regulation.

Authors:  Eric Johnson; Michele McTigue; Rebecca A Gallego; Ted W Johnson; Sergei Timofeevski; Michael Maestre; Timothy S Fisher; Robert Kania; Sansana Sawasdikosol; Steven Burakoff; Ciarán N Cronin
Journal:  J Biol Chem       Date:  2019-04-24       Impact factor: 5.157

2.  Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function.

Authors:  Yun Wang; Kelvin Zhang; Peter Georgiev; Steven Wells; Haiyan Xu; Brian M Lacey; Zangwei Xu; Jason Laskey; Robbie Mcleod; Joey L Methot; Mark Bittinger; Alexander Pasternak; Sheila Ranganath
Journal:  PLoS One       Date:  2020-12-03       Impact factor: 3.240

Review 3.  A perspective on HPK1 as a novel immuno-oncology drug target.

Authors:  Sansana Sawasdikosol; Steven Burakoff
Journal:  Elife       Date:  2020-09-08       Impact factor: 8.140
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.